Spotlight
Clinical Role
Clinical
Supplement Spotlight
CE
Subscribe
Clinical Data Supporting Pneumococcal Vaccination
Key opinion leaders examine the pivotal clinical data that supported the FDA approvals of PCV15, PCV20, and PCV21, while also explaining the differences between polysaccharide and conjugate pneumococcal vaccines in terms of their induced immune responses and the durability of protection they offer.
EP: 1.Symptomatology and Transmission of Pneumococcal Infection
EP: 2.Manifestation of Pneumococcal Disease in Adults
EP: 3.High-Risk Populations for Severe Pneumococcal Infection
EP: 4.Patient Burden Associated with Pneumococcal Disease
EP: 5.Vaccination Efforts to Mitigate Pneumococcal Outbreaks
EP: 6.Comparing and Contrasting the Characteristics of the FDA-Approved Pneumococcal Vaccines
EP: 7.Target Patient Populations for Pneumococcal Vaccines
EP: 8.ACIP Recommendations for Pneumococcal Vaccination
EP: 9.Clinical Considerations for Pneumococcal Vaccination Scheduling
Now Viewing
EP: 10.Clinical Data Supporting Pneumococcal Vaccination
What is the key data that led to the FDA-approvals of PCV15, PCV20, and PCV21?
How do the polysaccharide and conjugate pneumococcal vaccines differ in terms of immune response and durability?
- Can you discuss the potential long-term benefits of using conjugate vaccines over polysaccharide vaccines in adult populations and vice versa?
Recent Videos
Related Content
